Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer-Reference-Cited by-同舟云学术

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

Published:2019-08 Issue:4 Volume:17 Page:e814-e821
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Thomsen Frederik B.^ORCID,Røder M. Andreas,Jakobsen Henrik,Langkilde Niels Christian,Borre Michael,Jakobsen Erik B.,Frey Anders,Lund Lars,Lunden Dagmar,Dahl Claus,Brasso Klaus

Funder

IMK Almene Fond

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference24 articles.

1. International variation in prostate cancer incidence and mortality rates;Center;Eur Urol,2012

2. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer;Boevee;Eur J Cancer,2010

3. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study;Rider;Eur Urol,2013

4. Prostate Cancer, Version 1.2016;Mohler;J Natl Compr Canc Netw,2016

5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur Urol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. Long-Term Periodic and Conditional Survival Trends in Prostate, Testicular, and Penile Cancers in the Nordic Countries, Marking Timing of Improvements;Cancers;2023-08-25

3. Treatment of intermediate-risk prostate cancer with active surveillance in the routine care—Long-term outcomes of a prospective noninterventional study (HAROW);Current Urology;2023-04-20

4. Association Between Receipt of Definitive Treatment for Localized Prostate Cancer and Adverse Health Outcomes: A Claims-Based Approach;Value in Health;2022-11

5. Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data;Cancers;2022-08-27